

General Information

Name: Prof. Dr. med. Klaus-Michael Debatin
Date of Birth: 06.12.1952
Gender: Male
Address: Department of Pediatrics and Adolescent Medicine, Ulm University, Eythstrasse 24, 89075 Ulm/Germany
Phone: +49 731 500 57001
E-Mail: klaus-michael.debatin@uniklinik-ulm.de
Current Positions: Chairman, Department of Pediatrics and Adolescent Medicine
Vice President, Ulm University
Deputy Coordinating Investigator, Collaborative Research Center (SFB) 1074 "Experimental models and clinical translation in leukemia"

Academic Education

1971-1978 Medical School, Universities of Ulm, Freiburg and Heidelberg

Academic Degrees

1997 Professor of Pediatrics, Ulm University
1990 Habilitation in Pediatrics, University of Heidelberg
1979 Doctorate degree (Dr. med.), University of Heidelberg

Professional Experience

2013-2015 CEO and Medical Director, Ulm University Hospital
2010-2013 Deputy Medical Director, Ulm University Hospital
2010-2014 Vice President Medicine, Ulm University
2004-2010 Dean, Medical Faculty, Ulm University
2003-2005 Chairman, Science Committee of the Medical Faculty, Ulm University
2002-2004 Vice Dean, Medical Faculty, Ulm University
1995-2002 Head, Division of Molecular Oncology, German Cancer Research Center
1997 Visiting Professor, St. Jude Children's Research Hospital, Memphis
Since 1997 Chairman, Department of Pediatrics, Ulm University
Physician-in-chief of Ulm University Children's Hospital
1994-1997 Head, Hematology/Oncology Section, University Children's Hospital, Heidelberg
1990-1994 Heisenberg Fellow of the German Research Council (DFG)
- National Cancer Institute, USA (Fogarty Fellow)
- German Cancer Research Center, Heidelberg
- Hôpital Necker, Paris
1987-1990 Head of Laboratory of Immunology and Hematology, University Children's Hospital, Heidelberg
1984-1990 Guest scientist, Division of Immunogenetics, German Cancer Research Center, Heidelberg
1983-1990 Clinical fellow and research fellow (Oncology/Immunology Section), University Children's Hospital, Heidelberg
1979-1982 Research fellow (DFG), Institute of Immunology, University of Heidelberg and Max-Planck-Institute for Immunobiology, Freiburg

Miscellaneous

Awards / Honors

2012 German Cancer Aid Award 2011
2011 Elected Member, European Academy of Cancer Sciences (ECCO)
2011 Career Award, European Cell Death Organisation (ECDO)
2008 ASM Prize 2008 (British Society for Haematology)
2007 Descartes Research Prize 2006 (European Science Fund)
2005 Member of the Heidelberg Academy of Sciences
2002 German Cancer Award
2001 Member of the National Academy of Sciences (Leopoldina)
1998 Wilhelm Warner Award for Cancer Research

1997 SmithKline Beecham Award for Clinical Research
 1996 "Presidential Lecture", International Histiocyte Society
 1991 Kind Philipp Award, Society for Pediatric Oncology and Hematology
 1990 Heisenberg Fellowship, German Research Council

Positions / Memberships

Since 2013 Member Senate Commission for Clinical Research (SGKF), German Research Council (DFG)
 Since 2013 Member, Board of Trustees German Cancer Aid
 Since 2012 Member, European Research Institute for Integrated Cellular Pathology (ERI-ICP)
 Since 2011 Member, Senate German Research Foundation (DFG)
 Since 2010 Member, Steering Committee, Dr. Mildred Scheel Foundation
 Since 2009 Member, Advisory Board, Association of German University Hospitals (VUD)
 Since 2009 Member, Advisory Board, Dr. Mildred Scheel Foundation (German Cancer Aid)
 2009-2015 Member of the Board, German Association of Medical Faculties (MFT)
 2005-2007 President ECDO
 2004-2010 Member, Scientific Advisory Board, European School of Hematology
 2004-2014 Member, Scientific Advisory Board, German Cancer Society (Head since 2009)
 Since 2003 Member, Scientific Advisory Board, Interdisciplinary Center for Clinical Research, Jena
 Since 2001 Member, Scientific Advisory Board, Children's Cancer Research Institute, Vienna
 2001-2014 Member, Scientific Advisory Board, Georg-Speyer-Haus, Research Institute Frankfurt
 Since 2001 Member, Executive Board, German Society for Pediatrics (DGKJ)
 2001-2003 Member, Executive Board, Medical Faculty, University of Ulm
 1999-2004 Member, Senate Commission Cancer Research, German Research Council (Hinterzartener Kreis)
 1999-2002 Program Coordinator, Interdisciplinary Center for Clinical Research Ulm
 Since 1997 Member, Steering Committee, Tumor Center Ulm
 Since 1994 Member, Executive Committee, European Cell Death Organization (ECDO)
 Since 1992 Member, Committee on Biology and Diagnosis IBFM-Study group
 1993-1997 Program coordinator, Tumor Center Heidelberg / Mannheim

Publications

1. Trentin L, Queudeville M, Eckhoff S, Hasan M, Münch V, Boldrin E, Seyfried F, Enzenmüller S, Debatin KM*, Meyer LH*. Leukemia reconstitution in vivo is driven by cells in early cell cycle and low metabolic state. **Haematologica**. 2018;103(6):1008-17. *Equal contribution
2. Münch V, Trentin L, Herzig J, Demir S, Seyfried F, Kraus JM, Kestler H, Köhler R, Barth T, Te Kronnie G, Debatin KM*, Meyer, LH*. Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor. **Blood**. 2017;130(5):643-654. *Equal contribution
3. Schirmer M, Trentin L, Queudeville M, Seyfried F, Demir S, Tausch E, Stilgenbauer S, Eckhoff S, Meyer LH*, Debatin KM*. Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. **Cell Death Dis**. 2016;14;7:e2052. *Equal contribution.
4. Loeder S, Schirmer M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, Bertrand MJ, Vandenabeele P, Jeremias I, Debatin KM, Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. **Leukemia**. 2012;26(5):1020-29.
5. Meyer LH, Eckhoff S, Queudeville M, Kraus J, Giordan M, Stursberg J, Zangrando A, Vendramini E, Moricke A, Zimmermann M, Schrauder A, Lahr G, Holzmann K, Schrappe M, Basso G, Stahnke K, Kestler H, Te Kronnie G, Debatin KM. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. **Cancer Cell**. 2011;19(2):206-17.

6. Meyer LH, Karawajew L, Schrappe E, Ludwig W, Stahnke K, Debatin KM. Cytochrome c related caspase activation determines treatment response and relapse in childhood B-precursor ALL. **Blood**. 2006;107(11):4524-31.
7. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. **Nat Med**. 2002;8(8):808-15.
8. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug induced apoptosis in leukemia cell. **Nat Med**. 1996;2(5):574-77.
9. Debatin KM, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in adult T cell leukemia, **Lancet**. 1990;335(8688):497-500.
10. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. **Science**. 1989;245(4915):301-05.